Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):183–192. doi: 10.1097/QAI.0000000000001578

Figure 2. Impact of a 1 year implementation (a) infections averted, (b) new infections, (c) QALYS gained.

Figure 2

Note: The decrease in infections averted at the 20-year time horizon can be attributed to the generation of new infections by the patients on treatment that are living longer and have a greater number of opportunities to spread HIV. In the base case scenario, however, these individuals do not have the long term potential to infect others due to the high probability of death.